HUT64848A - Medical preparatives for preventing and treating osteoporises after menopausa - Google Patents

Medical preparatives for preventing and treating osteoporises after menopausa Download PDF

Info

Publication number: HUT64848A
Authority: HU; Hungary
Prior art keywords: ipriflavone; estrogen; treatment; estrogens; day
Prior art date: 1991-02-01

Application number

HU9302183A

Other languages

English (en)

Hungarian (hu)

Other versions

HU9302183D0 (en

Inventor

Paolo Chiesi

Original Assignee

Chiesi Farma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-01

Filing date

1992-01-28

Publication date

1994-03-28

1992-01-28 Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa

1993-10-28 Publication of HU9302183D0 publication Critical patent/HU9302183D0/hu

1994-03-28 Publication of HUT64848A publication Critical patent/HUT64848A/hu

Links

229960005431 ipriflavone Drugs 0.000 claims description 52
SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 claims description 49
229940011871 estrogen Drugs 0.000 claims description 47
239000000262 estrogen Substances 0.000 claims description 47
229940035811 conjugated estrogen Drugs 0.000 claims description 43
238000011282 treatment Methods 0.000 claims description 24
239000004480 active ingredient Substances 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 claims description 9
206010027304 Menopausal symptoms Diseases 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 6
208000017657 Menopausal disease Diseases 0.000 claims description 5
208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 4
239000008203 oral pharmaceutical composition Substances 0.000 claims 2
239000007901 soft capsule Substances 0.000 claims 1
210000000988 bone and bone Anatomy 0.000 description 15
239000002775 capsule Substances 0.000 description 14
230000000694 effects Effects 0.000 description 13
239000000203 mixture Substances 0.000 description 11
239000000902 placebo Substances 0.000 description 11
229940068196 placebo Drugs 0.000 description 11
229910052500 inorganic mineral Inorganic materials 0.000 description 10
239000011707 mineral Substances 0.000 description 10
235000012054 meals Nutrition 0.000 description 8
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
238000009472 formulation Methods 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
206010065687 Bone loss Diseases 0.000 description 5
208000001132 Osteoporosis Diseases 0.000 description 5
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 5
229960004127 naloxone Drugs 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
229940057917 medium chain triglycerides Drugs 0.000 description 3
239000000186 progesterone Substances 0.000 description 3
229960003387 progesterone Drugs 0.000 description 3
230000004044 response Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
102000055006 Calcitonin Human genes 0.000 description 2
108060001064 Calcitonin Proteins 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
239000001828 Gelatine Substances 0.000 description 2
241000700159 Rattus Species 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000004097 bone metabolism Effects 0.000 description 2
229960004015 calcitonin Drugs 0.000 description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
230000002357 endometrial effect Effects 0.000 description 2
230000001076 estrogenic effect Effects 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
239000008172 hydrogenated vegetable oil Substances 0.000 description 2
230000009245 menopause Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000008347 soybean phospholipid Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
238000011285 therapeutic regimen Methods 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
230000001457 vasomotor Effects 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
206010007269 Carcinogenicity Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
206010030247 Oestrogen deficiency Diseases 0.000 description 1
206010067572 Oestrogenic effect Diseases 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
206010039984 Senile osteoporosis Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
208000026723 Urinary tract disease Diseases 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
231100000260 carcinogenicity Toxicity 0.000 description 1
230000007670 carcinogenicity Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000013066 combination product Substances 0.000 description 1
229940127555 combination product Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
239000003687 estradiol congener Substances 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
208000020694 gallbladder disease Diseases 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000005802 health problem Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
150000002515 isoflavone derivatives Chemical class 0.000 description 1
235000008696 isoflavones Nutrition 0.000 description 1
238000009533 lab test Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000001592 luteinising effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000012502 risk assessment Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
229940083466 soybean lecithin Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
208000014001 urinary system disease Diseases 0.000 description 1
230000001836 utereotrophic effect Effects 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
235000019222 white chocolate Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HU9302183A 1991-02-01 1992-01-28 Medical preparatives for preventing and treating osteoporises after menopausa HUT64848A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ITMI910253A IT1244697B (it)	1991-02-01	1991-02-01	Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale

Publications (2)

Publication Number	Publication Date
HU9302183D0 HU9302183D0 (en)	1993-10-28
HUT64848A true HUT64848A (en)	1994-03-28

Family

ID=11358374

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU9302183A HUT64848A (en)	1991-02-01	1992-01-28	Medical preparatives for preventing and treating osteoporises after menopausa

Country Status (9)

Country	Link
EP (1)	EP0569415A1 (it)
AU (1)	AU1188492A (it)
CA (1)	CA2101547A1 (it)
HU (1)	HUT64848A (it)
IE (1)	IE920219A1 (it)
IT (1)	IT1244697B (it)
NZ (1)	NZ241418A (it)
WO (1)	WO1992013538A1 (it)
ZA (1)	ZA92661B (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0693927A4 (en) *	1993-04-16	1997-05-28	Univ Tufts Med	METHOD FOR TREATING MENAUPOSIC AND PREMENSTRUAL SYMPTOMS
HU212932B (en) *	1993-08-02	1996-12-30	Chinoin Gyogyszer Es Vegyeszet	Parmaceutical composition containing ipriflavone, hydroxyapatit and tricalciumphosphate for treating lack of bones and process for producing the composition
US6319914B1 (en)	1993-11-05	2001-11-20	Apollo Biopharmaceuticals, Inc.	Cytoprotective effect of polycyclic phenolic compounds
US5554601A (en) *	1993-11-05	1996-09-10	University Of Florida	Methods for neuroprotection
US5506211A (en) *	1994-05-09	1996-04-09	The Uab Research Foundation	Genistein for use in inhibiting osteroclasts
US6326365B1 (en)	1999-07-20	2001-12-04	Apollo Biopharmaceutics, Inc.	Methods of prevention and treatment of ischemic damage
US6339078B1 (en)	1999-07-20	2002-01-15	University Of Florida Research Foundation, Inc.	Methods of prevention and treatment of ischemic damage
CA2441252A1 (en) *	2001-03-16	2002-10-10	Wyeth	Estrogen replacement therapy
EP2081570A2 (en)	2006-10-24	2009-07-29	David W. Krempin	Anti-resorptive and bone building dietary supplements and methods of use

1991
- 1991-02-01 IT ITMI910253A patent/IT1244697B/it active IP Right Grant
1992
- 1992-01-24 IE IE021992A patent/IE920219A1/en unknown
- 1992-01-27 NZ NZ241418A patent/NZ241418A/xx unknown
- 1992-01-28 EP EP92903484A patent/EP0569415A1/en not_active Ceased
- 1992-01-28 CA CA002101547A patent/CA2101547A1/en not_active Abandoned
- 1992-01-28 AU AU11884/92A patent/AU1188492A/en not_active Abandoned
- 1992-01-28 WO PCT/EP1992/000174 patent/WO1992013538A1/en not_active Application Discontinuation
- 1992-01-28 HU HU9302183A patent/HUT64848A/hu unknown
- 1992-01-30 ZA ZA92661A patent/ZA92661B/xx unknown

Also Published As

Publication number	Publication date
ZA92661B (en)	1992-10-28
NZ241418A (en)	1993-03-26
ITMI910253A0 (it)	1991-02-01
WO1992013538A1 (en)	1992-08-20
AU1188492A (en)	1992-09-07
IE920219A1 (en)	1992-08-12
ITMI910253A1 (it)	1992-08-01
CA2101547A1 (en)	1992-08-02
IT1244697B (it)	1994-08-08
HU9302183D0 (en)	1993-10-28
EP0569415A1 (en)	1993-11-18

Legal Events

Date	Code	Title	Description
1995-05-29	DFC4	Cancellation of temporary protection due to refusal

Publication	Publication Date	Title
JP3113269B2 (ja)	2000-11-27	骨粗鬆症治療剤
DE602004002591T2 (de)	2007-08-09	Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
JP3208482B2 (ja)	2001-09-10	避妊製剤
US4590213A (en)	1986-05-20	Anti-anxiety method
JP2003095971A (ja)	2003-04-03	骨粗鬆症治療剤または組成物
US4970237A (en)	1990-11-13	Use of clomiphene to increase bone mass in premenopausal women
HUT64848A (en)	1994-03-28	Medical preparatives for preventing and treating osteoporises after menopausa
AU2017206480B2 (en)	2020-01-23	Composition, containing Loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome
EP3833370A1 (en)	2021-06-16	Compositions for use in the treatment of obesity
US4820736A (en)	1989-04-11	Use of clomiphene to predict fertility in a human female
Breslau	1994	Calcium, estrogen, and progestin in the treatment of osteoporosis
AU2008235006A1 (en)	2008-10-16	New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
Nakamura et al.	1991	Treatment of uterine leiomyomata with a luteinizing hormonereleasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women
Maddox	1992	Women at midlife: Hormone replacement therapy
KR102225792B1 (ko)	2021-03-09	에키노크롬 a를 유효성분으로 함유하는 폐경기 증후군의 치료 또는 예방용 약학적 조성물
US20220160734A1 (en)	2022-05-26	Treatment of fibroids with vitamin d and an agent such as epigallocatechin gallate (egcg)
RU2220712C1 (ru)	2004-01-10	Средство и набор для нормализации функциональных нарушений, возникающих в предклимактерический и климактерический период
JPH07109222A (ja)	1995-04-25	骨粗鬆症予防及び治療剤
JP3248170B2 (ja)	2002-01-21	コンドロイチン硫酸蛋白複合体含有食品
AU692155B2 (en)	1998-06-04	Method and composition for treatment of osteoporosis
Hale et al.	2000	Exploring the role of progestins and phytoestrogens in menopause
JP4465963B2 (ja)	2010-05-26	高脂血症の予防または改善用組成物
JPH1129488A (ja)	1999-02-02	ピコスルファートナトリウムを含有する医薬組成物
US20200129573A1 (en)	2020-04-30	Use of euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females
Avioli et al.	1998	Osteoporosis: the clinical problem